Cancer immunotherapy works, but how to find which patients will benefit? – BioPharma Dive
Is stories |
Cancer immunotherapy works, but how to find which patients will benefit?
BioPharma Dive Much ink has been spilled trying to puzzle out why Bristol-Myers Squibb's star immunotherapy Opdivo (nivolumab) failed a key study in non-small cell lung cancer last summer. The stunning setback surprised many across the industry and upended the … Research and Markets Has Announced the Launch of their Bristol-Myers Squibb Market Research Portal |
